A guide for when meningioma tumors need extra lab tests
Original title: An evidence-based workflow for integrating molecular testing with histopathology in the workup of meningiomas.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked back at tumors already taken out, so it is not a treatment you can ask for.
The short version
Doctors studied 1058 meningioma tumors to learn which ones need extra lab tests.
What was studied. Researchers looked at 1058 meningioma tumors that had been removed by surgery. They compared what each tumor looked like under a microscope with results from gene and DNA tests.
What they found. How fast the tumor cells were dividing was the strongest single sign of trouble. Tumors with two or more unusual microscope features were the most likely to come back. Tumors with fast dividing cells did poorly no matter what the gene tests showed.
What this means, and what it doesn't
What it could mean: This may help doctors pick which tumors are worth sending for extra lab tests. The team thinks those tests add the most for tumors with slow dividing cells.
What it doesn't mean: This is not a new treatment, and it does not change the surgery or drugs you get. It is one study that looked back at tumors already removed. Other teams still need to check these ideas before they become normal care. It is not a promise about your own tumor, and it is not a cure.
Source: PubMed, October 1, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.